The Food and Drug Administration (FDA) rejected Moderna’s application for a flu vaccine, overruling the recommendations of its own staff, STAT News reported yesterday. The decision, made by Dr. Prasad, raises further questions about the influence of political pressure on the agency’s scientific evaluations under the Trump-Kennedy administration.
The rejection comes amid growing concerns about increasing political interference within the FDA, as detailed in a STAT investigation published in October 2025. That report, based on interviews with over 20 current and former FDA staff, revealed a bureaucracy feeling pressure from above. Lizzy Lawrence, the STAT reporter who led the investigation, too reported on the decision regarding the Moderna vaccine.
Recent personnel changes within the Department of Health and Human Services (HHS) may also be contributing to the shifting landscape at the FDA. National Institutes of Health (NIH) Director Jay Bhattacharya is taking on the additional role of acting CDC director, replacing Jim O’Neill, who has been nominated to lead the National Science Foundation. Chelsea Cirruzzo and Anil Oza of STAT News first reported the details of these appointments.
The FDA’s decision regarding the Moderna flu vaccine is not occurring in a vacuum. A parallel trend shows decreasing rates of early prenatal care in the United States. Data from the National Center for Health Statistics indicates that the percentage of pregnant people beginning prenatal care in their first trimester decreased from 78.3% in 2021 to 75.5% in 2024 – the lowest rate since data collection began in 2016. This decline mirrors earlier findings from the nonprofit March of Dimes.
Meanwhile, a growing number of men’s health startups are advocating for routine semen analysis, framing it as a potential “pap smear for men” to assess both fertility and overall health. The idea, championed by physician Paul Turek, is based on research showing correlations between sperm health and conditions like metabolic disorders, cardiovascular disease, and cancer. However, not all experts agree on the benefits of widespread semen analysis.
The debate over treatment options for obesity also highlights a divergence between patient preferences and medical recommendations. Despite evidence suggesting that bariatric surgery may be more effective at weight loss and improving related health markers, GLP-1 medications are gaining popularity, with usage climbing 67% in 2024 while surgeries fell by 13%. The cost of GLP-1s, at $5,200 annually, is significantly lower than the $24,215 price tag for surgery.
Endocrinologist Jody Dushay has observed a troubling trend among patients using GLP-1 medications: an excessive focus on weight loss to the detriment of overall health improvements. In a recent essay, Dushay described encountering increasing numbers of patients who become fixated on reaching a specific weight, potentially leading to disordered eating patterns.
The FDA has not yet responded to requests for comment regarding the specific rationale behind the Moderna vaccine rejection, nor has it addressed concerns about potential political influence on its decision-making processes.
